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ABSTRACT
Objectives: FOXA1 expression has been demonstrated in several hormone-dependent cancers. However, data are lim-
ited concerning the role of FOXA1 in endometrial cancers. The present study aimed to investigate FOXA1 expression via 
the microarray technique in benign hyperplasia, endometrial intraepithelial neoplasia, and endometrial endometrioid 
carcinoma. We also aimed to determine whether there were any associations between FOXA1 expression, tumor grade, 
myometrial invasion and lymphatic invasion.
Material and methods: Paraffin-embedded sections prepared from samples obtained from 114 patients who underwent 
surgical hysterectomy or curettage were analyzed. Data were retrieved from digitally-stored medical records. Tissue 
microarrays were prepared from formalin-fixed, paraffin-embedded tissue blocks. Full tumor sections were used for im-
munohistochemical analysis performed.
Results: Carcinomas with nuclear grade 3 had higher FOXA1 values than others, while grade 2 carcinomas also had higher 
FOXA1 values relative to grade 1 (p < 0.001). FOXA1 values of FIGO stage III carcinomas were significantly higher than others 
and stage II values were also significantly higher than stage I FOXA1 values (p < 0.001). Patients with myometrial and lymph 
node invasion had significantly higher FOXA1 values than others (p < 0.001 and p = 0.047, respectively). FOXA1 had 91.30% 
sensitivity, 63.60% specificity and 77.78% accuracy for predicting the presence of myometrial invasion with a cut-off value of 9.
Conclusions: FOXA1 expression is higher in endometrial endometrioid carcinoma compared to benign endometrial 
hyperplasia or intraepithelial neoplasia. In patients with endometrial endometrioid carcinoma, high FOXA1 expression is 
associated with high tumor grade, myometrial and lymph node invasion. However, FOXA1 expression is not associated 
with lymphovascular or cervical invasion.
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INTRODuCTION
Worldwide, endometrial cancer is the sixth most com-
mon malignancy in women and the most common ma-
lignant tumor of the female genital tract [1, 2]. Temporal 
studies have demonstrated a considerable increase in the 
frequency of endometrial cancer in developed and develop-
ing countries [3, 4]. Endometrial cancer has been generally 
categorized into two types as the most frequently seen 
estrogen-dependent endometrial endometrioid (Type 1), 
and estrogen independent non-endometrioid carcinoma 
(Type 2) [5]. Benign endometrial hyperplasia (BH) and en-
dometrial intraepithelial neoplasia (EIN) are assumed as 
histopathological precursors in the development process of 
endometrioid carcinoma [6]. Mutations in the PTEN, PIK3CA, 
K-RAS, and CTNNBI and microsatellite instability have been 
demonstrated to act in the pathogenesis of these tumors [7]. 
Extended exposure to estrogens is believed to give rise 
to the development of estrogen-dependent type endome-
trial cancer. Unopposed exposure to estrogen causes over 
activation of estrogen receptor α which leads to prolifera-
tion via the upregulation of growth factors including EGF 
and IGF-1 [8]. Several co-activators and co-repressors are 
known to regulate the activity of the estrogen receptor- α. 
Forkhead box A1 (FOXA1), a member of the Forkhead Box 
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transcription factor family, has been reported to increase 
estrogen receptor- α activity by promoting the binding of 
estrogen receptors [9]. FOXA1 binding to DNA is known to 
alter chromatin structure and promote the binding of tran-
scription factors such as estrogen receptor- α. The patho-
logical role of FOXA1 expression has been demonstrated in 
several hormone-dependent cancers. While the presence 
of FOXA1 expression has been related to good prognosis 
in estrogen receptor- positive breast cancers. Conflicting 
results have been derived from studies investigating its role 
in prostate cancer [10–12]. In addition to contrasting find-
ings, there is limited data concerning the role of FOXA1 in 
endometrial cancer and its histopathological precursors.  
Objectives
The present study was aimed to investigate FOXA1 ex-
pression in BH, EIN, and endometrial endometrioid car-
cinoma using the microarray technique. Additionally, we 
aimed to investigate whether any relationship exists be-
tween FOXA1 expression and the tumor grade, myometrial, 
and lymphatic invasion of endometrial cancers.
MATeRIAl AND MeTHODS 
The study group was retrospectively selected from 
145 patients who had undergone hysterectomy or curet-
tage at Antalya Training and Research Hospital from Janu-
ary 2014 to December 2018. Among these, 20 were ex-
cluded due to the lack of viable pathological specimens 
or insufficient clinical data, while 11 were excluded due to 
low-quality immunohistochemistry (IHC) results. The re-
maining 114 were included into the study, of which 45 had 
undergone simple hysterectomy and 69 had undergone 
curettage. All patients who had undergone simple hyster-
ectomy (n = 45) had received lymph dissection. Repeat IHC 
staining was not performed, the available specimens were 
re-evaluated.
Paraffin-embedded sections were utilized for all meas-
urements; and specimens without sufficient tissue sample 
and those with histopathologically inconclusive results 
were excluded from the evaluation. The demographic and 
clinical data of all individuals were retrieved from digitally 
stored medical records. Histological grading of the tumors, 
myometrial, cervical and invasion patterns were determined 
according to the FIGO (International Federation of Gynecol-
ogy and Obstetrics) criteria [13]. The study was approved by 
Ethics Committee of University of Health Sciences, Antalya 
Education and Research Hospital (11/3, 2018). 
Tissue microarrays (TMAs) prepared using triplicate 
approximately 2 mm tissue cores of tumor samples that 
provided ideal representation of the tumor and invasion 
area, were placed into a single recipient paraffin block, using 
a semi-automated instrument and targeted cores prepared 
by two experienced pathologists (HTY and CSA).  Immuno-
histochemical analyses were performed using FOXA1 pri-
mary monoclonal antibody (at 1:500 dilution, ab173287, 
Abcam, USA). Sections of 4-µm- thick TMAs were mounted 
on poly-L-lysine coated slides.  Immunohistochemical analy-
sis was performed using BOND-III Fully Automated IHC & ISH 
Staining System (Leica Microsystems, Germany). Antigen 
retrieval was performed using FOXA1 primary monoclonal 
antibody (pH 6) left in citrate buffer for 10-minutes. Sec-
tions were exposed to 3% hydrogen peroxide for 5-minutes, 
incubated with the primary antibody for 30 minutes, using 
3,3’diamino benzidine as a chromogen for 5-minutes and 
hematoxylin as a counter stain for 5 minutes.  
All cases were evaluated for nuclear staining status of the 
tumor cells by the same two experienced pathologists (HTY, 
CSA). Each specimen was assessed by both pathologists 
and a consensus result was deemed as the result. Briefly, 
five fields with at least 100 tumor cells were evaluated. Any 
intensity of nuclear staining of FOXA1 in ≥ 1% of the tumor 
cells was considered positive regarding the control sample 
intensities (prostate cancer cell nuclear staining intensity). 
As we were focused on determining whether specimens 
were positive or negative for FOXA1, we did not utilize any 
specific scoring system. The pathologists were able to reach 
a consensus decision on all samples; thus, there were no 
inconclusive results within the final reports. All cases were 
scored without prior knowledge of diagnosis or pathological 
stage of tumor. When the staining intensity was weak and 
deemed as nonspecific, then background staining was not 
evaluated. TMA cores with inadequate tumor samples for 
evaluation were not included in the end results. Sections of 
prostatic carcinoma were used as positive control for FOXA1.
The SPSS version 21 software was used for all analy-
ses. Normality of distribution was checked with the Shap-
iro-Wilk test. Data were given as mean ± standard deviation 
(SD) and median (minimum-maximum) where and when 
appropriate. Comparison of FOXA1 values between groups 
were performed through non-parametric tests due to lim-
ited patient numbers, by the Mann-Whitney U test or Kruskal 
Wallis test, depending on group count. Post-hoc pair wise 
comparisons were made by using the Bonferroni correction 
method. The relationship between age and FOXA1 values 
was evaluated by calculation of the Spearman Correla-
tion Coefficient. The performance of FOXA1 values for the 
prediction of myometrial invasion was calculated via Re-
ceiver Operating Characteristics (ROC) Curves. Values with 
P ≤ 0.05 were accepted as statistically significant.
ReSulTS
We included 114 patients into our study and the 
mean age of the patients was 53.75 ± 10.63 years.) Patients 
had endometrial endometrioid carcinoma (n = 71, 62.28%), 
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Figure 2. Figure demonstrating increasing FOXA1 expression levels with increasing tumor grade and FIGO stage
Figure 1. FOXA1 expression pattern in endometrial carcinoma: 
A strongly positive immunohistochemical staining (x 40)  
BH (n = 22, 19.3%), and EIN (n = 21, 18.42%). FOXA1 values 
were significantly higher in endometrial endometrioid car-
cinoma compared to the other groups (p < 0.001). Addition-
ally, FOXA1 values were found to be significantly correlated 
with age (r = 0.465 p < 0.001).
Most of the carcinomas were nuclear grade 2 (n = 40, 
56.34%) while 17 (23.94%) carcinomas were grade 1 and 
14 (19.72%) carcinomas were grade 3 (Fig. 1). Carcinomas 
with nuclear grade 3 had higher FOXA1 values than others, 
and grade 2 had higher values than grade 1 (p < 0.001). 
Thirty-three (46.48%) carcinomas were histological grade 1, 
31 (43.66%) grade 2, and 7 (9.86%) grade 3. Akin to nuclear 
grade, those with higher histological grade had higher 
FOXA1 values (p < 0.001). When we evaluated FIGO stage, we 
found that 28 (39.44%) carcinomas were stage I, 29 (40.85%) 
were stage II, and 14 (19.72%) were stage III. The FOXA1 val-
ues of our patients demonstrated a significant increase with 
each grade (p < 0.001, Fig. 2). 
Twenty-three patients had myometrial invasion and 
these patients had significantly higher FOXA1 values com-
pared to those without (p < 0.001). The most common in-
vasion pattern was well-circumscribed invasion (44.44%). 
Ten patients had lymphovascular, eight cervical and six 
lymph node invasion. There were no significant differences 
for FOXA1 values regarding the invasion pattern, and the 
presence or absence of lymphovascular or cervical invasion. 
Patients with lymph node invasion had significantly higher 
FOXA1 values than those without (p = 0.047) (Tab. 1). 
When we evaluated the capability of FOXA1 expression 
for the prediction of myometrial invasion, we found that 
FOXA1 had 91.3% sensitivity, 63.6% specificity and 77.78% 
accuracy for predicting the presence of myometrial invasion 
with a cut-off value of 9 (Tab. 2).
DISCuSSION
The present study shows that patients with endometrial 
endometrioid carcinoma have higher FOXA1 expression 
compared to those with BH or EIN. Furthermore, FOXA1 ex-
pression was significantly increased in patients with higher 
grade endometrial endometrioid cancer. In addition, higher 
FOXA1 expression was found to be associated with tumor 
invasion.
FOXA1, a member of the FOX family of transcription fac-
tors, is acknowledged as a modulator of estrogen receptors 
in breast and androgen receptors in prostate cancer. Studies 
focused on breast cancer have revealed that FOXA1 triggers 
not only the development but also the progression of the 
disease, and it is essential for both estrogen receptor activ-
ity and its expression [14]. In addition, overexpression of 
FOXA1 has been suggested to prevent metastatic progres-
sion, either by altering the expression of BRCA1 -associated 
cell cycle inhibitor or directly stimulating transcription of the 
E-cadherin gene (CDH1), which results in the induction of 
E-cadherin expression and decreases the migration of can-
cer cells [15]. This dual action in breast cancers may indicate 
that FOXA1 may promote progression in the early stages of 
the tumor but suppresses progression in advanced stage. 
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Mean ± SD  Median (Min–Max)  p 
Age (years) 
≤ 55  53  11.57 ± 21.43  3 (0–90) 
< 0.001 
> 55  61  21.84 ± 24.63  10 (0–90) 
Diagnosis 
BHa  22  0.95 ± 2.42  0 (0–10) 
< 0.001 EINa  21  2.00 ± 3.26  0 (0–10) 
ECab  71  26.51 ± 25.67  20 (0–90) 
Nuclear Grade (ECa) 
Grade 1a  17  7.18 ± 5.04  5 (2–20) 
< 0.001 Grade 2b  40  20.50 ± 16.50  17.5 (0–60) 
Grade 3c  14  67.14 ± 17.94  60 (45–90) 
Histological Grade (ECa) 
Grade 1a  33  8.06 ± 4.80  6 (0–20) 
< 0.001 Grade 2b  31  35.68 ± 22.19  25 (8–90) 
Grade 3b  7  72.86 ± 17.04  70 (50–90) 
FIGO Stage (ECa) 
Stage Ia  28  7.71 ± 4.58  6 (0–20) 
< 0.001 Stage IIb  29  25.03 ± 17.22  20 (5–60) 
Stage IIIc  14  67.14 ± 17.94  60 (45–90) 
Myometrial Invasion 
Absent  22  12.27 ± 13.52  6 (2–50) 
< 0.001 
Present  23  37.30 ± 28.57  25 (5–90) 
Invasion Patterns 
Well-circumscribed  20  22.50 ± 21.45  15 (2–70) 
0.640 
Diffusely Stromal  8  29.38 ± 30.41  17.5 (5–90) 
Adenomyosis-like  10  22.50 ± 27.99  9 (5–85) 
MELF  7  31.14 ± 31.56  20 (8–90) 
Lymphovascular Invasion 
Absent  35  23.14 ± 24.86  10 (2–90) 
0.116 
Present  10  31.80 ± 28.39  20 (8–90) 
Cervical Invasion 
Absent  37  22.92 ± 24.31  10 (2–90) 
0.102 
Present  8  35.00 ± 30.71  20 (10–90) 
Lymph Node Invasion 
Absent  39  22.26 ± 23.73  10 (2–90) 
0.047 
Present  6  43.33 ± 32.04  45 (10–90) 
Same letters denote lack of significant differences between groups. BH — benign endometrioid hyperplasia, ECa — endometrioid carcinoma, MELF — micro 
cystic, elongated and fragmented pattern








Area under ROC curve  0.842 ± 0.059 
p  < 0.001 
In breast cancer, FOXA1 expression has been demonstrated 
to be associated with various clinicopathological features 
and favorable outcomes including overall survival, breast 
cancer-specific survival, and relapse-free survival [16–18]. 
In contrast to breast cancer, FOXA1 expression is associated 
with reactivation of androgen receptor which plays a critical 
role in the development and progression of prostate cancer 
[19]. Overexpression of FOXA1 has been shown to be a pre-
dictor for poor outcome in prostate cancer [20].
Endometrial endometrioid cancer is nearly identical to 
breast cancer regarding the role of estrogen receptors, as 
estrogen receptor expression has been reported as a pow-
erful prognostic marker [21]. In a preliminary study inves-
tigating FOXA1 expression in 109 cases with endometrial 
cancer, Abe et al. [22], found that FOXA1 expression was 
negatively associated with lymph node status. Moreover, 
exogenous FOXA1 application has been reported to sup-
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press both the proliferation and migration of endometrial 
cancer cells [22]. Recently, Tangen et al., investigated the 
role of FOXA1 expression in a larger population including 
529 primary and 199 metastatic endometrial carcinoma 
lesions and found that low FOXA1 levels were associated 
with a worse prognosis among estrogen receptor -nega-
tive patients. However, in those with estrogen receptor 
positivity, five-year survival was similar in patients with low 
or high FOXA1 expression [23]. In contrast to the findings 
of previous studies, our results indicate that FOXA1 ex-
pression is associated with high tumor grade, lymph node 
invasion and myometrial invasion. This inconsistency may 
be due to the recruitment of patients with endometrial 
endometrioid cancer where estrogen receptor expression 
is common. In addition, several studies have demonstrated 
that the majority of endometrial carcinomas also express 
androgen receptors in addition to estrogen receptors. Qiu 
et al. [24], in their study which evaluated 76 endometrial 
cancer specimens, demonstrated that FOXA1 expression 
was significantly correlated with androgen receptor expres-
sion, which was higher in advanced grade endometrial 
cancer, suggesting that FOXA1 might promote cell prolif-
eration through androgen receptors. In other words, the 
interaction between androgen receptors and FOXA1 might 
be the actual cause of tumor proliferation in endometrial 
cancer; thus, providing an explanation to our results which 
were in contrast with most of the literature. Therefore, we 
speculate that the impact of FOXA1 on the development 
and progression of endometrial endometrioid carcinoma 
may be associated with the differences in the expression 
of estrogen and androgen receptors. 
We believe that further studies are warranted to deter-
mine the exact mechanism by which FOXA1 impacts lymph 
node and myometrial invasion. Nevertheless, our results 
indicate that FOXA1 levels are associated with increased 
tumor grade and lymph node invasion which are conflicting 
with some of the results of previous research. 
There are some limitations to be mentioned concerning 
the present study. These data must be interpreted with cau-
tion because of the relatively low sample size and the few 
number of patients enrolled with endometrial endometrioid 
carcinoma. Due to the lack of the follow-up, we could not 
provide data regarding the survival rates. In addition, we 
could not investigate estrogen and androgen receptor ex-
pressions in our samples, which may have provided further 
data to determine the effects of FOXA1 on disease progres-
sion; however, it is commonly acknowledged that endome-
trial endometrioid carcinomas estrogen receptor-positive 
tumors. Although we could obtain limited information from 
our scarce number of study patients, we believe that our 
findings will point to a critical role for FOXA1 in endometrial 
endometrioid cancer. 
CONCluSIONS
FOXA1 expression is higher in patients with endometrial 
endometrioid carcinoma compared to those with BH or EIN. 
In patients with endometrial endometrioid carcinoma, high 
FOXA1 expression is associated with high tumor grade, 
myometrial invasion and lymph node invasion. However, 
we have found no association between FOXA1 expression 
and cervical or lymphovascular invasion. Considering the 
conflicting results in the literature and the interesting char-
acteristics of FOXA1 expression, we have indicated that 
further studies are needed to elucidate the role of FOXA1 in 
endometrial endometrioid carcinoma.
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